No abstract

No abstract

Aim: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects. Objective: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects. Primary outcome observe change in HbA1c, FBS and PPBS from baseline to 48 weeks. Secondary outcome is to note the change in BMI and drug safety. Method: A retrospective analysis of data from December 2016 till December 2017 was carried out at 4 centers of a chain of Diacare-Diabetes care and Hormone Clinic. The inclusion criteria included newly detected type 2 subjects aged 50.0 +_ 7.0 years, who were Drug naïve with mean HbA1c 8.0% (7%-9%), mean Fasting value 144 mg/dl (+/- 18mg/dl) and mean post meal value 220mg/dl (+/-18mg/dl). All vital parameters with anthropometric data was analyzed, tabulated and reviewed Result: N=450 subjects. Reduction in HbA1c after 12 weeks was 1.2% from base line and after 24 weeks it was 1.6% and 1.0% at the end of 48 weeks. 66% of subjects were seen with HbA1c <7% at 24th week. To the rest in whom target was not achieved till 24th weeks, an interventation was added in the form of OHA along with physical exercise and diet. Drop in BMI at 12 weeks was 0.6 kg/m2, at 24th week it was 0.8 kg/m2 and at 48th week it was 0.5kg/m2. 8% of subjects had an AE-intermittent diarrhea and no SAE was detected. Conclusion: In real scenario, combination of tenegliptin 20mg with metformin 1000mg was associated with clinically significant reduction in HbA1c. Disclosure D.B. Chudasama: None. B.D. Saboo: None. D. Panchal: None. F. Patel: None. M. Saiyed: None. D. Hasnani: None. V. Chavda: None. H. Chandarana: None. R. Goklani: None.

No abstract

No abstract